BCG was proud to send a team of experts to San Francisco alongside the J.P. Morgan Healthcare Conference, January 13-15, 2025, to engage with leading experts in health care innovation and investment.
The 2025 J.P. Morgan Healthcare Conference convened business and health care executives for a full slate of discussions about the future of the industry. BCG experts were on the ground alongside the event, and our health care practitioners are eager to discuss the highlights with our clients, to help implement the latest innovations and capitalize on the investment trends shaping the industry in 2025. Stay tuned for details on our presence alongside the event, and our presence alongside the 2026 conference.
Learn more about BCG’s latest work with health care clients.
BCG and Zeiss developed an application to give prospective patients fast, accurate, validated answers about elective treatments.
LEARN MORE
How BCG used a cascaded and holistic organization-design approach to help a global biotech firm reduce its gross labor and non-labor costs by 20%.
LEARN MORE
BCG X partners to leverage new AI tools and platform to enhance clinical trials, speeding up medical innovations, life-changing therapies, and patient outcomes.
LEARN MORE
Our GenAI Collaboration with Merck
This year, BCG launched a collaboration with Merck aimed at advancing the discovery and assessment of novel drug targets for chronic and degenerative diseases through AI.
BCG’s second annual report reviews the growth of new drug modalities over the past year and addresses the potential impact on the biopharmaceutical industry.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Costs for genomic sequencing have dropped steeply, making new types of genetic tests more accessible and changing the business model for the labs that run them.
The rise of GenAI brings tremendous opportunity. But to cut through the hype and identify future winners, investors should focus on four innovation hot spots.
The global biopharma company’s chief data and technology officer discusses its initiative to inject digital capabilities across the value chain and the importance of prioritizing patient outcomes.
